drugset

drugset / Trial / NCT00675870

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

NCT00675870 ↗

Phase 2 Unknown 65 enrolled NuRx Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether NRX 195183 is effective in the treatment of relapsed or refractory Acute Promyelocytic Leukemia

Timeline

Start: 2008-04
Primary completion: 2010-04
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NRX 195183	Small molecule	—	Oral

Indications